Skip to main content
Evidence: BGrowth HormoneAnti-Aging & Longevity

GHRP-2: Benefits, Dosage & FDA Status

Growth Hormone Releasing Peptide 2

A potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.

FDA Status

Not FDA-approved — research compound; previously studied as growth hormone deficiency diagnostic

Typical Dose

100–300 mcg, 1–3 times daily (subcutaneous)

Evidence Grade

BLimited clinical + robust preclinical evidence

Half-Life

~15–30 minutes

Routes of Administration

subcutaneous

First Synthesized

1990s

Clinics Indexed

86 providers have offered GHRP-2 in our tracked directory.

Mechanism of Action

Hexapeptide GHS-R1a agonist that drives a sharp pulsatile GH release.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.

Reported Side Effects

  • Hunger surge
  • Cortisol/prolactin elevation
  • Water retention

Contraindications

  • Active malignancy
  • Pregnancy

Commonly Stacked With

Regulatory & Safety Context

FDA status: Not FDA-approved — research compound; previously studied as growth hormone deficiency diagnostic

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on GHRP-2. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 10084610
  2. PubMed PMID 9272332

Last reviewed: 2026-04-30

← Back to all peptides